Beam Therapeutics Inc.
HealthcareNASDAQ:BEAM · NASDAQ Global Select
-$0.38 today
Vol 1.57M · Avg 2.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.5%
avg -21.1%
ROIC
-27.4%
avg -0.0%
ROA
-5.4%
avg -69.0%
Analysis
ROA is currently the strongest return metric at -5.4% versus its period average of -69.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John Evans | Chief Executive Officer & Director | $1.43M | — | 48 | $19,676.00 | 0.02% |
Sravan Kumar Emany | Chief Financial Officer | $1.30M | — | 48 | $105,456.00 | 0.10% |
Giuseppe Ciaramella | President | $1.18M | — | 57 | $218,406.00 | 0.21% |
Amy Simon | Chief Medical Officer | $897,685.00 | — | 61 | $102,735.00 | 0.10% |
Christine Bellon | Chief Legal Officer & Corporate Secretary | $834,189.00 | — | 60 | $109,711.00 | 0.11% |
J. Keith Joung | Co-Founder | — | — | — | — | — |
Manmohan Singh | Chief Technology Officer | — | — | — | — | — |
Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer | — | — | — | $51,171.00 | 0.05% |
Gopi Shanker | Chief Scientific Officer | — | — | — | — | — |
David R. Liu | Co-Founder | — | — | — | $0.00 | <0.01% |
Feng Zhang | Co-Founder | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
28
$8.59M
Net Sentiment
$8.59M
Net selling
Most Active
Evans John M.
9 transactions
1–10 of 28
Analysis
Insiders reported 0 buys worth $0.00 and 28 sells worth $8.59M over the last 12 months. That adds up to net selling of $8.59M. Evans John M. was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +36.5% (9yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +36.5% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages BEAM?
Beam Therapeutics Inc. (BEAM) lists 11 active executives. The top listed executive is Amy Simon, Chief Medical Officer.
Are BEAM insiders buying or selling?
Recent insider activity shows net selling of $7.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.